D/E 0.02 — less debt than most Healthcare peers (≈25th pctile)
P/E10.8xA
P/E 10.8 — cheapest decile in Healthcare (≈10th pctile)
PEG0.36est.A
PEG 0.36 — exceptional; paying well under fair value for growth · PEG derived: P/E ÷ forward 1-year analyst EPS growth, because this name has no vendor-supplied PEG. Same earnings-growth basis as the reported figure on other rows.
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 72
Quality96.5
Growth66.3
Value70.7
Why this score
Short track record
Entry · Margin of safety
52-week rangeNear 52-week high
5% off the 12-month high
vs DCF fair value5% aboveest. fair value ~$84
What the price assumes: free cash flow compounding at ~16% a year for the next decade — vs the ~25% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability74% · Agross profit ÷ total assets (Novy-Marx)
ROIC21.5% · Areturn on invested capital — not score-weighted
Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.
Why now
Hinge Health is a high-quality compounder leveraging technology to automate musculoskeletal system care (MSK), a critical and growing health segment. Our model assigns a strong Quality score of 96/100, reflecting its robust fundamentals, including a 15.1% profit margin and an impressive 31.7% ROE. With revenue growth at 49.8% FY YoY and a compelling 0.19 PEG ratio, the company is rapidly scaling its personalized MSK platform to self-insured employers, whose adoption drives persistent top-line expansion.
Moat
The company's durable edge stems from its proprietary technology stack, specifically its AI-powered motion tracking and unique electrical nerve stimulation wearable device, which automate and personalize MSK care. This specialized offering for acute injury, chronic pain, and post-surgical rehabilitation creates high switching costs for self-insured employers, who integrate Hinge Health into their benefits. The exceptional 31.7% ROE is a direct result of this technological differentiation and the stickiness of its platform in a high-value healthcare niche.
Risk
Despite strong current growth, the Bull Rankings model flags a 'Short track record' and a weaker Growth pillar score of 68/100, indicating skepticism about the long-term durability of its rapid expansion. Our Reverse DCF analysis implies only ~12%/year free-cash-flow growth sustained for 10 years, which is significantly below the current 49.8% FY YoY revenue growth. This disconnect suggests the market is pricing in a substantial deceleration, despite the current low P/E of 9.7. A sustained deceleration in revenue growth below 20% or a material increase in competition within the digital MSK space would confirm this bearish outlook.
Horizon
1-3 yr $106.47 (15-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $134.41 at ~9% CAGR — dividend + buyback compounding. 10 yr $172.38 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
HNGE vs the Top Picks average
Pillar
HNGE
Book avg
Diff
Quality
0.97
0.84
+0.13
Growth
0.66
0.87
-0.21
Value
0.71
0.76
-0.05
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · HNGE
Trend
0.0 over 47 daily scores
From 72.0 (Jun 22) → 72.0 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
30-day change
-8.0%
90-day change
+0.2%
Forward EPS estimate
$3.13
Over the last 90 days, what analysts expect HNGE to earn is essentially unchanged. The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Position sizing · HNGE
$
%
%
Shares to buy
22
Position size
$1,945
3.9% of portfolio
Stop price
$66.31
25% below $88.42
$ at risk if stopped
$486.31
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Hinge Health, Inc. (HNGE): score, valuation & FAQ
Hinge Health, Inc. (HNGE) is a Health Information Services company that scores 72 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A), P/E (A) and PEG (A). On valuation, HNGE sits about 5% above our discounted-cash-flow fair value — the current price implies roughly 16% annual free-cash-flow growth over the next decade.
Is HNGE a good stock to buy?
Bull Rankings scores HNGE 72 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A), P/E (A) and PEG (A). A score is a quantitative screen of Hinge Health, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does HNGE score 72 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). HNGE earns its highest marks on Rev (A), P/E (A) and PEG (A). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is HNGE overvalued or undervalued?
Based on $88.42, HNGE sits about 5% above our discounted-cash-flow fair value — the current price implies roughly 16% annual free-cash-flow growth over the next decade. It trades at a 10.8x P/E (graded A). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in HNGE?
Despite strong current growth, the Bull Rankings model flags a 'Short track record' and a weaker Growth pillar score of 68/100, indicating skepticism about the long-term durability of its rapid expansion. Our Reverse DCF analysis implies only ~12%/year free-cash-flow growth sustained for 10 years, which is significantly below the current 49.8% FY YoY revenue growth. This disconnect suggests the market is pricing in a substantial deceleration, despite the current low P/E of 9.7. A sustained deceleration in revenue growth below 20% or a material increase in competition within the digital MSK space would confirm this bearish outlook.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.